Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO.
The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol …
Sanofi CEO Paul Hudson emphasized the company’s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon
Last week, the House Judiciary Committee came out with a report about CVS Health’s alleged antitrust behavior toward disruptive pharmacy models that provide digital services
✂️ Sanofi culls several programs: The move comes as part of its “regular portfolio reviews,” a spokesperson said in an email. One candidate affected was
The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted
Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO.
The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol …